LIXTE Biotechnology Transforms into AI Energy Infrastructure Platform, Adds Denham Capital Founder to Board

June 1st, 2026 2:05 PM
By: Newsworthy Staff

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic shift to focus on AI energy infrastructure equipment and services, appointing Denham Capital founder Stuart D. Porter to its board, while seeking a partner for its cancer drug operations.

LIXTE Biotechnology Transforms into AI Energy Infrastructure Platform, Adds Denham Capital Founder to Board

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform aimed at supporting the growing power demands of artificial intelligence and hyperscale data centers. As part of the transition, Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined the company’s board of directors. The move signals a major pivot for the clinical-stage pharmaceutical company, which will now target power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies. At the same time, LIXTE said it is seeking a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations focused on cancer treatments.

The announcement underscores the escalating energy needs of the AI sector. Hyperscale data centers, which power AI workloads, are projected to consume significantly more electricity in the coming years, driving demand for innovative infrastructure solutions. LIXTE’s new strategy positions it to capitalize on this trend by providing equipment and services for power generation and distribution. The addition of Porter, who founded Denham Capital, a global infrastructure and energy investment firm, brings deep expertise in energy investments. Denham Capital has managed over $11 billion in capital commitments across energy and infrastructure sectors.

LIXTE’s legacy operations include its lead compound LB-100, a first-in-class PP2A inhibitor being studied in clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Through its wholly owned subsidiary, Liora Technologies Europe Ltd., the company also develops electronically controlled proton therapy systems for cancer treatment. The company stated that it will continue to support these programs while exploring a strategic transaction. “We believe this strategic pivot positions LIXTE to address one of the most critical challenges facing the AI industry: reliable and scalable power infrastructure,” the company said in the release.

Investors can access the full press release at https://ibn.fm/MVXfg. Additional information about LIXTE is available at www.lixte.com.

Source Statement

This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,

blockchain registration record for the source press release.
;